Hydroxychloroquine with or without Azithromycin in Mild-to-Moderate Covid-19.
Alexandre Biasi Cavalcanti,Fernando G. Zampieri,Regis Goulart Rosa,Luciano Cesar Pontes Azevedo,Viviane C Veiga,Alvaro Avezum,Lucas P. Damiani,Aline Marcadenti,Leticia Kawano-Dourado,Thiago Lisboa,Debora L. M. Junqueira,Pedro Gabriel Melo de Barros e Silva,Lucas Tramujas,Erlon Oliveira de Abreu-Silva,Lígia Nasi Laranjeira,Aline T. Soares,Leandro S. Echenique,Adriano José Pereira,Flávio Geraldo Resende Freitas,Otavio Gebara,Vicente C.S. Dantas,Remo H.M. Furtado,Eveline P. Milan,Nicole A. Golin,Fábio F. Cardoso,Israel Silva Maia,Conrado R. Hoffmann Filho,Adrian P.M. Kormann,Roberto Bleuel Amazonas,Monalisa Fernanda Bocchi de Oliveira,Ary Serpa-Neto,Maicon Falavigna,Renato D. Lopes,Flávia Ribeiro Machado,Otavio Berwanger +34 more
Reads0
Chats0
TLDR
Among patients hospitalized with mild-to-moderate Covid-19, the use of hydroxychloroquine, alone or with azithromycin, did not improve clinical status at 15 days as compared with standard care.Abstract:
Background Hydroxychloroquine and azithromycin have been used to treat patients with coronavirus disease 2019 (Covid-19). However, evidence on the safety and efficacy of these therapies is...read more
Citations
More filters
Journal ArticleDOI
Heart Disease and Stroke Statistics—2022 Update: A Report From the American Heart Association
TL;DR: The American Heart Association, through its Statistics Committee, continuously monitors and evaluates sources of data on heart disease and stroke in the United States to provide the most current information available in the annual Statistical Update as discussed by the authors .
Journal Article
Coronavirus disease (COVID-19) pandemic.
Lekhraj Rampal,B S Liew +1 more
TL;DR: In this article, the authors proposed a method to solve the problem of "no abstracts" and "no-no-expansions" in the context of artificial intelligence.
Journal ArticleDOI
SARS-CoV-2 Neutralizing Antibody LY-CoV555 in Outpatients with Covid-19.
Peter Chen,Ajay Nirula,Barry Heller,Robert L. Gottlieb,Joseph Boscia,Jason Morris,Gregory D. Huhn,Jose Cardona,Bharat Mocherla,Valentina Stosor,Imad Shawa,Andrew C. Adams,Jacob Van Naarden,Kenneth L. Custer,Lei Shen,Michael Durante,Gerard J. Oakley,Andrew E. Schade,Janelle Sabo,Dipak R. Patel,Paul Klekotka,Daniel Skovronsky +21 more
TL;DR: In this interim analysis of a phase 2 trial, one of three doses of neutralizing antibody LY-CoV555 appeared to accelerate the natural decline in viral load over time, whereas the other doses had not by day 11.
Journal ArticleDOI
Severe Covid-19
TL;DR: Key Clinical Points Evaluation and Management of Severe Covid-19 Patients with severe coronavirus disease 2019 (Covid- 19) may become critically ill with acute respiratory distress syndrome that typ...
Journal ArticleDOI
Effect of Hydroxychloroquine in Hospitalized Patients with Covid-19
Peter Horby,M Mafham,Louise Linsell,Jennifer L Bell,Natalie Staplin,Jonathan Emberson,Martin Wiselka,Andrew Ustianowski,E Elmahi,B Prudon,Tony Whitehouse,Timothy Felton,John Williams,J Faccenda,Jonathan Underwood,J K Baillie,Lucy C Chappell,Saul N. Faust,Thomas Jaki,Katie Jeffery,Wei Shen Lim,Alan A Montgomery,Kathy Rowan,Joel Tarning,James A Watson,Nicholas J. White,Edmund Juszczak,Richard Haynes,Martin J Landray +28 more
TL;DR: In patients hospitalized with COVID-19, hydroxychloroquine was not associated with reductions in 28-day mortality but was associated with an increased length of hospital stay and increased risk of progressing to invasive mechanical ventilation or death.
References
More filters
Journal ArticleDOI
The REDCap consortium: Building an international community of software platform partners.
Paul A. Harris,Paul A. Harris,Robert Taylor,Brenda L. Minor,Veida Elliott,Michelle Fernandez,Lindsay O'Neal,Laura McLeod,Giovanni Delacqua,Francesco Delacqua,Jacqueline Kirby,Stephany N. Duda +11 more
TL;DR: The Research Electronic Data Capture (REDCap) data management platform was developed in 2004 to address an institutional need at Vanderbilt University, then shared with a limited number of adopting sites beginning in 2006, and a broader consortium sharing and support model was created.
Journal ArticleDOI
Remdesivir for the Treatment of Covid-19 - Final Report.
John H. Beigel,Kay M. Tomashek,Lori E. Dodd,Aneesh K. Mehta,Barry S. Zingman,Andre C. Kalil,Elizabeth L. Hohmann,Helen Y. Chu,Annie Luetkemeyer,Susan Kline,Diego Lopez de Castilla,Robert W. Finberg,Kerry Dierberg,Victor F. Tapson,Lanny Hsieh,Thomas F. Patterson,Roger Paredes,Daniel A. Sweeney,William R. Short,Giota Touloumi,David Chien Lye,Norio Ohmagari,Myoung-don Oh,Guillermo M. Ruiz-Palacios,Thomas Benfield,Gerd Fätkenheuer,Mark G. Kortepeter,Robert L. Atmar,C. Buddy Creech,JD Lundgren,Abdel G. Babiker,Sarah Pett,James D. Neaton,Timothy Burgess,Tyler Bonnett,Michelle Green,Mat Makowski,Anu Osinusi,Seema U Nayak,H. Clifford Lane +39 more
TL;DR: The data show that remdesivir was superior to placebo in shortening the time to recovery in adults who were hospitalized with Covid-19 and had evidence of lower respiratory tract infection.
Journal ArticleDOI
Baseline Characteristics and Outcomes of 1591 Patients Infected With SARS-CoV-2 Admitted to ICUs of the Lombardy Region, Italy.
Giacomo Grasselli,Giacomo Grasselli,Alberto Zangrillo,Alberto Zanella,Alberto Zanella,Massimo Antonelli,Massimo Antonelli,Luca Cabrini,Antonio Castelli,Danilo Cereda,Antonio Coluccello,Giuseppe Foti,Roberto Fumagalli,Giorgio Antonio Iotti,Nicola Latronico,Luca Lorini,Stefano Merler,Giuseppe Natalini,Alessandra Piatti,Marco Ranieri,Anna Mara Scandroglio,Enrico Storti,Maurizio Cecconi,Antonio Pesenti,Antonio Pesenti +24 more
TL;DR: Patients with coronavirus disease 2019 (COVID-19) requiring treatment in an intensive care unit (ICU) in the Lombardy region of Italy were characterized, including data on clinical management, respiratory failure, and patient mortality.
Journal ArticleDOI
A Trial of Lopinavir-Ritonavir in Adults Hospitalized with Severe Covid-19.
Bin Cao,Yeming Wang,Danning Wen,Wen Liu,Jingli Wang,Guohui Fan,Lianguo Ruan,Bin Song,Yanping Cai,Ming Wei,Xingwang Li,Jia'an Xia,Nanshan Chen,Jie Xiang,Ting Yu,Tao Bai,Xuelei Xie,Li Zhang,Caihong Li,Ye Yuan,Hua Chen,Huadong Li,Hanping Huang,Shengjing Tu,Fengyun Gong,Ying Liu,Yuan Wei,Chongya Dong,Fei Zhou,Xiaoying Gu,Jiuyang Xu,Zhibo Liu,Yi Zhang,Li Hui,Lianhan Shang,Ke Wang,Kunxia Li,Xia Zhou,Xuan Dong,Zhaohui Qu,Sixia Lu,Xujuan Hu,Shunan Ruan,Shanshan Luo,Jing Wu,Lu Peng,Fang Cheng,Lihong Pan,Jun Zou,Chunmin Jia,Juan Wang,Xia Liu,Shuzhen Wang,Xudong Wu,Qin Ge,Jing He,Haiyan Zhan,Fang Qiu,Li Guo,Chaolin Huang,Thomas Jaki,Frederick G. Hayden,Peter Horby,Dingyu Zhang,Chen Wang +64 more
TL;DR: In hospitalized adult patients with severe Covid-19, no benefit was observed with lopinavir–ritonavir treatment beyond standard care, and future trials in patients withsevere illness may help to confirm or exclude the possibility of a treatment benefit.
Journal ArticleDOI
Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial.
Philippe Gautret,Jean-Christophe Lagier,Philippe Parola,Van Thuan Hoang,Line Meddeb,M. Mailhe,Barbara Doudier,Johan Courjon,Valérie Giordanengo,Vera Esteves Vieira,Hervé Tissot Dupont,Stéphane Honoré,Philippe Colson,Eric Chabrière,Bernard La Scola,Jean-Marc Rolain,Philippe Brouqui,Didier Raoult +17 more
TL;DR: Hydroxychloroquine treatment is significantly associated with viral load reduction/disappearance in COVID-19 patients and its effect is reinforced by azithromycin, which was significantly more efficient for virus elimination.
Related Papers (5)
Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial.
Philippe Gautret,Jean-Christophe Lagier,Philippe Parola,Van Thuan Hoang,Line Meddeb,M. Mailhe,Barbara Doudier,Johan Courjon,Valérie Giordanengo,Vera Esteves Vieira,Hervé Tissot Dupont,Stéphane Honoré,Philippe Colson,Eric Chabrière,Bernard La Scola,Jean-Marc Rolain,Philippe Brouqui,Didier Raoult +17 more
Remdesivir for the Treatment of Covid-19 - Final Report.
John H. Beigel,Kay M. Tomashek,Lori E. Dodd,Aneesh K. Mehta,Barry S. Zingman,Andre C. Kalil,Elizabeth L. Hohmann,Helen Y. Chu,Annie Luetkemeyer,Susan Kline,Diego Lopez de Castilla,Robert W. Finberg,Kerry Dierberg,Victor F. Tapson,Lanny Hsieh,Thomas F. Patterson,Roger Paredes,Daniel A. Sweeney,William R. Short,Giota Touloumi,David Chien Lye,Norio Ohmagari,Myoung-don Oh,Guillermo M. Ruiz-Palacios,Thomas Benfield,Gerd Fätkenheuer,Mark G. Kortepeter,Robert L. Atmar,C. Buddy Creech,JD Lundgren,Abdel G. Babiker,Sarah Pett,James D. Neaton,Timothy Burgess,Tyler Bonnett,Michelle Green,Mat Makowski,Anu Osinusi,Seema U Nayak,H. Clifford Lane +39 more
Dexamethasone in Hospitalized Patients with Covid-19
Peter Horby,Wei Shen Lim,Jonathan Emberson,M Mafham,Jennifer L Bell,Louise Linsell,Natalie Staplin,Christopher E. Brightling,Andrew Ustianowski,E Elmahi,B Prudon,Christopher A Green,Timothy Felton,David Chadwick,K Rege,C Fegan,Lucy C Chappell,Saul N. Faust,Thomas Jaki,Katie Jeffery,Alan A Montgomery,Kathryn M Rowan,Edmund Juszczak,J K Baillie,Richard Haynes,Martin J Landray +25 more
A Trial of Lopinavir-Ritonavir in Adults Hospitalized with Severe Covid-19.
Bin Cao,Yeming Wang,Danning Wen,Wen Liu,Jingli Wang,Guohui Fan,Lianguo Ruan,Bin Song,Yanping Cai,Ming Wei,Xingwang Li,Jia'an Xia,Nanshan Chen,Jie Xiang,Ting Yu,Tao Bai,Xuelei Xie,Li Zhang,Caihong Li,Ye Yuan,Hua Chen,Huadong Li,Hanping Huang,Shengjing Tu,Fengyun Gong,Ying Liu,Yuan Wei,Chongya Dong,Fei Zhou,Xiaoying Gu,Jiuyang Xu,Zhibo Liu,Yi Zhang,Li Hui,Lianhan Shang,Ke Wang,Kunxia Li,Xia Zhou,Xuan Dong,Zhaohui Qu,Sixia Lu,Xujuan Hu,Shunan Ruan,Shanshan Luo,Jing Wu,Lu Peng,Fang Cheng,Lihong Pan,Jun Zou,Chunmin Jia,Juan Wang,Xia Liu,Shuzhen Wang,Xudong Wu,Qin Ge,Jing He,Haiyan Zhan,Fang Qiu,Li Guo,Chaolin Huang,Thomas Jaki,Frederick G. Hayden,Peter Horby,Dingyu Zhang,Chen Wang +64 more